Tags Archives: unfractionated heparin

thumbnail
0 comment

Comparison of Anticoagulation Strategies…

Abstract Objectives:  Extracorporeal membrane oxygenation is a life-sustaining therapy for severe respiratory failure. Extracorporeal membrane oxygenation circuits require systemic anticoagulation that creates a delicate balance between circuit-related thrombosis and bleeding-related..

Read More
thumbnail
0 comment

Pharmacokinetic model of unfractionated…

Abstract Background: Unfractionated heparin (UFH) is widely used as a reversible anti-coagulant in cardiopulmonary bypass (CPB). However, the pharmacokinetic characteristics of UFH in CPB surgeries remain unknown because of the..

Read More
thumbnail
0 comment

Comparison of Anticoagulation Strategies…

Abstract OBJECTIVES:  Extracorporeal membrane oxygenation is a life-sustaining therapy for severe respiratory failure. Extracorporeal membrane oxygenation circuits require systemic anticoagulation that creates a delicate balance between circuit-related thrombosis and bleeding-related..

Read More
thumbnail
0 comment

How to best monitor…

Abstract Introduction Unfractionated heparin is widely used as an anticoagulant for extracorporeal life support (ECLS) and usually monitored with activated partial thromboplastin time (aPTT). Due to its limitations in pediatric..

Read More
thumbnail
0 comment

Activated Clotting Times Demonstrate…

Abstract Background:  The optimal monitoring strategy for anticoagulation management in extracorporeal membrane oxygenation (ECMO) remains a clinical controversy. The Extracorporeal Life Support Organization Anticoagulation Guidelines suggest that multiple anticoagulation assays..

Read More
thumbnail
0 comment

Evaluation of Unfractionated Heparin…

Abstract Purpose: To evaluate unfractionated heparin (UFH) dosing guided by antifactor Xa levels during targeted temperature management (TTM) post-cardiac arrest. Methods: Single-center, retrospective, observational study between January 1, 2014 and..

Read More
thumbnail
0 comment

Bivalirudin vs. heparin in…

Abstract Aims Unfractionated heparin (UFH) has been the primary anticoagulant of choice on extracorporeal membrane oxygenation (ECMO). However, it is debatable whether bivalirudin (BIV), a direct thrombin inhibitor, may be..

Read More
thumbnail
0 comment

Predicting Therapeutic Response to…

Abstract Background: Unfractionated heparin (UFH) is an anticoagulant drug that is considered a high-risk medication because an excessive dose can cause bleeding, whereas an insufficient dose can lead to a..

Read More
thumbnail
0 comment

Resistance to unfractionated heparin…

Abstract Because of its rapid onset and offset of action, and its ability to be fully and rapidly reversed with protamine when anticoagulation control is needed, unfractionated heparin (UFH) remains..

Read More
thumbnail
0 comment

Anti-Xa assay monitoring improves…

Abstract Unfractionated heparin (UFH) is the most used anticoagulant in patients receiving veno-venous extracorporeal membrane oxygenation (VV-ECMO). Its therapeutic levels are monitored using activated partial thromboplastin time ratio (aPTTr) or..

Read More
thumbnail
0 comment

Factors Influencing Unfractionated Heparin…

Abstract Background Unfractionated heparin (UFH) is commonly used during cardiac surgery with a cardiopulmonary bypass to prevent blood clotting. However, empirical administration of UFH leads to variable responses. Pharmacokinetic and..

Read More
thumbnail
0 comment

Factors Influencing Anti-Xa Assays:…

Abstract Background The presence of dextran sulfate (DS) in reagents and the type of blood collection tube (citrate/citrated-theophylline-adenosine-dipyridamole [CTAD]) can lead to discrepancies between unfractionated heparin (UFH) anti-Xa levels. Objectives ..

Read More
thumbnail
0 comment

Andexanet Alfa Neutralizes the…

Abstract Introduction Andexanet alfa (AA) - zhzo, recombinant coagulation factor Xa, is an approved antidote for oral Xa inhibitors (apixaban and rivaroxaban). Unfractionated heparin (UFH) is commonly used for therapeutic,..

Read More
thumbnail
0 comment

Consumptive coagulopathy: how low-dose…

Abstract Bleeding and thrombotic complications are major drivers in extracorporeal life support (ECLS) patients’ negative outcomes and are reported in up to 40% of the ECLS-runs [1, 2]. Consumptive coagulopathy..

Read More
thumbnail
0 comment

Factors Affecting the Discrepancy…

Abstract In unfractionated heparin (UFH) monitoring during extracorporeal circulation, the traditional measures of activated clotting time (ACT) or activated partial thromboplastin time (APTT) may diverge, confounding anticoagulant adjustments. We aimed..

Read More
thumbnail
0 comment

Pleiotropic Effects of Heparin…

Abstract Unfractionated heparin (UFH) was uncovered in 1916, has been used as an anticoagulant since 1935, and has been listed in the World Health Organization's Model List of Essential Medicines...

Read More
thumbnail
0 comment

HEMA-Lysine-Based Cryogels for Highly…

Abstract Unfractionated heparin (UFH) and its low-molecular-weight fragments (LMWH) are widely used as anticoagulants for surgical procedures and extracorporeal blood purification therapies such as cardiovascular surgery and dialysis. The anticoagulant..

Read More
thumbnail
0 comment

Evaluating the Use of…

Abstract Background Evidence supporting  with unfractionated heparin (UFH) in patients with an intra-aortic balloon pump (IABP) to prevent  remains limited, while bleeding risks remain high. Monitoring heparin in this setting with anti-factor..

Read More
thumbnail
0 comment

Unfractionated heparin monitoring by…

Abstract Introduction No clear guidelines exist for unfractionated heparin (UFH) monitoring in adult patients on veno-arterial extracorporeal life support (VA-ECLS) for refractory cardiogenic shock. In this study, we sought to..

Read More
thumbnail
0 comment

Troubleshooting heparin resistance

Abstract The term heparin resistance is likely best defined as the failure of an appropriate dose of unfractionated heparin (UFH) to achieve a predetermined level of anticoagulation. Unfortunately, and despite..

Read More
thumbnail
0 comment

Factors associated with activated…

Abstract Introduction The recently recommended activated clotting time (ACT) to be maintained at the initiation of and during cardiopulmonary bypass (CPB) is ≥480 s. However, the post-unfractionated heparin (UFH) administration ACT..

Read More
thumbnail
0 comment

Performance of Hemochron ACT-LR…

Abstract Objectives According to the manufacturer, the Hemochron ACT-LR cuvette is designated for heparin concentrations of 0 to 2.5 IU/mL, while the optimal concentration range for the ACT+ cartridge is..

Read More
thumbnail
0 comment

Anticoagulation in ECMO: Target…

Abstract The 2021 Adult and Pediatric Anticoagulation Guidelines for patients on extracorporeal membrane oxygenation (ECMO) recommend a target partial thromboplastin time (PTT) between 60 and 85 seconds when unfractionated heparin..

Read More